06
Apr
2006
Great news for the Colorado bio-scape… Replidyne Inc., a Louisville, Colorado based drug company focused on anti-infectives, has filed a registration statement with the SEC for a proposed initial public offering of its common stock. It plans to trade on the Nasdaq under ticker symbol RDYN, with Merrill Lynch and Morgan Stanley serving as lead [...]
14
Feb
2006
Replidyne, Inc., and Forest Laboratories, Inc. (NYSE: FRX) announced that the two companies have entered into an agreement for the commercialization, development and distribution of Replidyne’s new oral antibiotic, faropenem medoxomil, in the United States. Under the terms of the agreement, Forest will make a $50 million upfront payment to Replidyne as well as potential [...]
25
Jan
2006
Replidyne, Inc., a biopharmaceutical company focused on the discovery and development of new anti-infective drugs, kicked off 2006 with a bang and has submitted a New Drug Application to the FDA for Orapem™ for the treatment of acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis and uncomplicated skin and skin structure infections. [...]
09
Sep
2005
Replidyne – NDA or Bust!
Posted in CO Public: Replidyne
Replidyne continues their charge towards the planned 4Q05 NDA filing for Faropenem, an antibiotic for the treatment of respiratory tract infections. To aid these efforts the company has just closed on a $62.5 million Series D financing led by several new investors including: Duquesne Capital Management, Healthcare Investment Partners and MDS Life Sciences. Also participating [...]
07
Jul
2005
(The first look at a Colorado Series A (well really B) company) Just a stones throw off of the Boulder Turnpike is where Replidyne resides. Under the leadership of Chief Executive Officer Ken Collins, Replidyne is focused upon discovering and developing novel anti-infective drugs to address a major, and growing, public health issue: bacterial resistance [...]
Life Science Deal Flow PARTNERS
-
